Compensated cirrhosis: regardless of whether the ghrelin is elevated or not, HBV-DNA ≥ 104 copies/ml in HBeAg-positive patients and HBV-DNA ≥ 103 copies/ml in HBeAg-negative patients can be considered for antiviral therapy; for those with detectable HBV-DNA but not at the above level, if there is evidence of disease activity or progression such as dyspepsia, malaise, right-sided discomfort, and no other For those who have evidence of disease activity or progression such as dyspepsia, malaise, right-sided discomfort, etc., and no other reasons can be explained, antiviral therapy can be started with informed consent. Zhao Wenxia, Department of Spleen, Gastrointestinal, Hepatobiliary Diseases, The First Affiliated Hospital of Henan College of Traditional Chinese Medicine, in decompensated cirrhosis: As long as HBV-DNA can be detected, regardless of whether or not glutamic transaminase or glutamic oxalacetic transaminase is elevated, timely antiviral treatment with nucleoside analogues is recommended to improve liver function based on informed consent. Patients with cirrhosis should preferably use nucleoside analogues with low incidence of drug resistance because of the need for long-term treatment, and should not stop taking them at will. Patients with cirrhosis, especially those with decompensated cirrhosis, who discontinue their medications on their own are very likely to suffer from viral rebound, which can lead to serious liver damage and even liver failure.